Thomas W. Burns

Thomas W. Burns, Chairman & Chief Executive Officer

Mr. Burns has served as our chief executive officer and as a member of our Board of Directors since March 2002. In December 2021, he was appointed Chairman of the Board. He also previously served as our president from March 2002 to March 2022. Mr. Burns was also a founder and member of the board of directors of DOSE Medical Corporation (acquired by Glaukos), serving as its chairman of the board from October 2009 until June 2019 and its chief executive officer and president from March 2010 until June 2015. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. He has raised nearly $400 million in enterprise capital in private and public offerings and has led and helped build multiple start-up companies. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices and pharmaceuticals, drug delivery technologies, surgical products and over-the-counter products. Prior to joining our Company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer and as a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery, of Bausch & Lomb from 1998 to 2000. In October 2020, Mr. Burns joined the board of directors of Pulmonx Corporation (Nasdaq: LUNG). He served on the board of directors of Avedro from July 2018 until his resignation on August 6, 2019, prior to its acquisition by Glaukos. Mr. Burns has also served as an entrepreneur in residence at Versant Ventures Management, LLC. Mr. Burns received a B.A. from Yale University.